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BDDrFVIII (Refacto AF) based on the difference in half-life reported, even if BDDrF-
VIII has a lower price per IU. [1] Recht et al. Hemophilia 2009:1–12; [2] EMA 
Assessment report Refacto AF. London March 2009. http://www.ema.europa.eu/
humandocs/PDFs/EPAR/Refacto/refactoaf-H-232-II-59-68-AR.pdf
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OBJECTIVES: To conduct cost-effectiveness and budget impact analysis (BIA) of 
OROS hydromorphone versus CR morphine and CR oxycodone for moderate to 
severe cancer pain from the public payer perspective in Brazil. METHODS: A decision 
tree followed by a Markov Model with a 12 month time horizon was developed with 
data from the Phase III trial Hanna 2008. The achievement of mild pain (worst pain 
scores < 4) was considered as outcome. Only direct medical costs were considered and 
unit costs were obtained from Brazilian ofﬁ cial lists. For the BIA, 10% of currently 
used CR morphine daily doses was substituted for equivalent OROS hydromorphone 
doses. The same rational was adopted for CR oxycodone comparison. Univariate 
deterministic sensitivity analyses showed that the results remained consistent through 
model parameters variation. RESULTS: OROS hydromorphone showed 1.66 addi-
tional months in mild pain per patient per year when compared to both CR morphine 
and CR oxycodone. Annual treatment costs were 2.401 BRL, 1.256 BRL and 5.114 
BRL for OROS hydromorphone, CR morphine and CR oxycodone respectively. The 
incremental cost-effectiveness ratio was 689 BRL per additional month in mild pain 
per patient per year, when OROS hydromorphone was compared to CR morphine. 
Versus CR oxycodone, OROS hydromorphone was more effective with fewer costs, 
being cost saving (ICER -1,634 BRL). BIA results showed that the substitution of 10% 
of current utilization of CR morphine for OROS hydromorphone and CR oxycodone 
would result in a budgetary impact of 118,722 BRL and 347,295 BRL, respectively. 
CONCLUSIONS: OROS hydromorphone is cost saving when compared to CR oxy-
codone and is more cost-effective than CR oxycodone when both are compared to 
the current scenario of chronic cancer pain treatment with CR morphine, with a lower 
budgetary impact.
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OBJECTIVES: Golimumab is a novel TNF-α inhibitor for treatment of patients with 
severe active ankylosing spondylitis (AS). This study evaluated the cost-effectiveness 
of golimumab and its appropriate comparators in the treatment of AS from UK 
National Health Service perspective. METHODS: A Markov model with an initial 
decision tree was developed to simulate the progression of a hypothetical cohort of 
active AS patients for 20 years. The primary outcome measure was quality-adjusted 
life-years (QALYs) estimated using Bath Ankylosing Spondilytis Functional Index 
(BASFI) whereas the primary response measure was ≥50% improvement in Bath 
Ankylosing Spondilytis Disease Activity Index (BASDAI) at 12 weeks. Direct costs 
including medication costs and AS management costs were included. Golimumab was 
compared with conventional treatment and other TNF-α inhibitors. Costs and out-
comes were discounted at 3.5%. RESULTS: All TNF-α inhibitors were superior to 
conventional treatment and comparable to each other on BASDAI response. The 
incremental cost-effectiveness ratio (ICER) for golimumab was £15,353 per QALY 
compared to conventional treatment. The probability of golimumab being cost-effec-
tive at a threshold of £30,000/QALY was 92%. Compared to etanercept and adali-
mumab, golimumab generated marginally more QALYs at marginally more costs. 
CONCLUSIONS: Golimumab may be considered as a cost-effective treatment alterna-
tive for patients with AS. With comparable costs and efﬁ cacy to other TNF-α inhibi-
tors, golimumab’s position in the treatment pathway is likely to be driven by patient 
and physician choice.
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OBJECTIVES: The Dutch reimbursement policy for expensive inpatient medicines 
requires outcomes research after four years of temporary reimbursement. Based on a 
retrospective study, we explored the cost-effectiveness of bortezomib for relapsed/
refractory multiple myeloma in Dutch daily practice. METHODS: Detailed clinical 
data from a real-world cohort of 72 patients treated with bortezomib and 67 patients 
never treated with bortezomib were collected from medical records. Validity of the 
incremental cost-effectiveness was assessed by comparing baseline prognosis between 
bortezomib and non-bortezomib patients. Clinical effectiveness was evaluated by 
comparing Kaplan-Meier survival estimates. Costs of resource use from a hospital 
perspective were based on patient-level data. RESULTS: Prognostic factors for bort-
ezomib patients were signiﬁ cantly different compared to non-bortezomib patients. 
Incremental analyses for bortezomib versus non-bortezomib patients were therefore 
not performed. Total mean costs and median survival from start of relapsed/refractory 
treatment for bortezomib patients were c84,042 and 33.2 months. Bortezomib 
accounted for 21% of total costs among these patients. For non-bortezomib patients, 
total mean costs and median survival from start of relapsed/refractory treatment were 
c54,435 and 21.6 months. The proportion of patients still in follow-up at the end of 
data collection was slightly higher in bortezomib versus non-bortezomib patients 
(51% vs. 46%). Total mean costs for bortezomib patients did not differ signiﬁ cantly 
when excluding patients still in follow-up. For non-bortezomib patients, total mean 
costs differed signiﬁ cantly when excluding patients still in follow-up, mainly due to 
high costs of lenalidomide treatment, stem cell transplants and inpatient hospital stays. 
CONCLUSIONS: Our real-world data challenged the assessment of the incremental 
cost-effectiveness of bortezomib versus other treatments in the indication of relapsed/
refractory multiple myeloma. It was possible to estimate the cost and effects for 
bortezomib patients in daily practice to determine the real-world value. Data synthesis 
incorporating effectiveness for the relevant comparator might facilitate estimation of 
a valid ICER.
PSY40
COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN 
REFRACTORY OUT-PATIENTS WITH NEUROPATIC PAIN FOLLOWED 
IN PRIMARY CARE SETTINGS
de Salas-Cansado M1, Pérez C2, Saldaña MT3, Navarro A4, Rejas J5
1Trial Form Support Spain, Madrid, Spain; 2Pain Clinic, Hospital de la Princesa, Madrid, Spain; 
3Primary Care Health Centre Raíces, Castrillón, Asturias, Spain; 4Primary Care Health Centre 
Puerta del Ángel, Madrid, Spain; 5Pﬁ zer España, Alcobendas/Madrid, Spain
OBJECTIVES: Estimate the cost-effectiveness of Pregabalin (PGB) versus Usual Care 
(UC) in refractory out-patients with Neuropathic Pain (NeP) treated according to 
usual medical practice in Primary Care settings (PCS) in Spain. METHODS: Data 
extracted from a 12-week non-interventional prospective study conducted to ascertain 
the cost of NeP were used. PGB naïve patients treated with UC or PGB, matched by 
age (+5 years), sex and pain intensity (+5 pts), refractory (≥40VAS-McGill) to previous 
treatment during the prior 6 months, were selected in a 1:1 ratio. Patients could switch 
to PGB (monotherapy/add-on) or to UC (non-narcotics, opiates, antidepressants and/
or anticonvulsants). Time horizon was 12 weeks. Effectiveness was quality-adjusted 
life-years (QALY) gain. Perspectives of the National Health Service (NHS) and society 
(2006) were included, and expressed as an incremental cost-effectiveness ratio (ICER). 
Bootstrapping techniques (10,000 re-samples) were used to obtain the probabilistic 
ICER, its 95% percentile conﬁ dence interval (CI) and the cost-effectiveness accept-
ability curve. RESULTS: A total of 160 patient-pairs were extracted. Compared with 
UC, PGB was associated with signiﬁ cantly higher QALY gain; 0.0374 ± 0.0367 vs. 
0.0224 ± 0.0313 (P < 0.001). Notably, although drug costs were higher for PGB (c251 
± 125 vs. c104 ± 121, P < 0.001), its QALY gain did not incur a higher overall total 
cost (c1335 ± 1302 vs. c1387 ± 1489; P = 0.587), nor higher health care costs (c529 
± 438 vs. c560 ± 672; p = 0.628). In fact, the ICER was dominant for total and health 
care costs, with CIs respectively, dominant-c17,268, and dominant-c6,508. ICER for 
drug costs was c10,672/QALY (dominant-c19,858). The 99% of the re-samples were 
below the threshold of c30,000/QALY. CONCLUSIONS: Versus usual care in the 
community medical setting, pregabalin is highly cost-effective in the treatment of 
refractory NeP patients. The high indirect costs and increased health care costs associ-
ated with the treatment of refractory patients, which offset higher cost of pregabalin, 
highlight the economic burden of the condition on society.
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OBJECTIVES: To evaluate cost-effectiveness of biologics used in patients with psoria-
sis in Colombia and Peru. METHODS: We estimated direct costs of etanercept, 
adalimumab, ustekinumab and inﬂ iximab based on their labels for ﬁ rst/induction year 
and second/maintenance year (EUR1 = COL$2340 = SOL$357). For etanercept we 
considered two induction schemes: 50 mg weekly 52 weeks-D1- and 100 mg 12 weeks 
followed by 50 mg 40 weeks-D2-. Effectiveness was evaluated as 75% reduction in 
Psoriasis Area and Severity Index-PASI 75- from meta-analysis presented by Hawkins 
et al. in the 14th International ISPOR: inﬂ iximab = 80%; ustekinumab = 69%; adali-
mumab = 59%; etanerceptD2- = 52%; etanerceptD1 = 39%. Inﬂ iximab and 
ustekinumab effectiveness were not signiﬁ cantly different. However, both were signiﬁ -
cantly superior to etanercept (D1 and D2). RESULTS: In Colombia, Ustekinumab was 
dominant (c29.012 in 2 years) generating cost savings of −c4.416 vs. etanerceptD1; 
−c7.411 vs. adalimumab; −c8.119 vs. etanerceptD2 and −c25,340 vs. inﬂ iximab; with 
higher or same effectiveness than the other biologics used in that country. In Peru, all 
the options were more effective and more costly than the standard of care (etaner-
ceptD1). The ICER per patient with PASI 75 of etanerceptD2, adalimumab, 
ustekinumab and inﬂ iximab, compared to etanerceptD1 were c21.654; c19,860, 
c13,036 and c29,008, respectively. Then, the efﬁ ciency frontier was formed by etan-
erceptD1, ustekinumab and inﬂ iximab. Given evidence shows the last two products 
do not have effectiveness signiﬁ cant differences, ustekinumab became the dominant 
